Vivacit-E Liner for Hip Osteoarthritis
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
How is the Vivacit-E Liner treatment different from other hip osteoarthritis treatments?
What is the purpose of this trial?
This trial is testing a special hip replacement part made from durable plastic in patients needing hip surgery. The goal is to see if it reduces wear and tear, improves pain, and enhances movement.
Research Team
Ryan Boylan, MBA
Principal Investigator
Zimmer Biomet
Eligibility Criteria
This trial is for adults aged 18-60 with hip conditions like osteoarthritis or avascular necrosis who need a new hip joint (total hip arthroplasty). They must be skeletally mature, have not had previous hip replacements on the affected side, and be able to follow the study's procedures and visits.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the Vivacit-E HXPE Liner with the Continuum acetabular shell implant
Initial Follow-up
Initial evaluation of the implanted Vivacit-E HXPE Liners for bedding in, and linear and volumetric wear
Long-term Follow-up
Participants are monitored for safety, device survivorship, and functional outcomes using various scores and radiographic analysis
Treatment Details
Interventions
- Vivacit-E Liner
Find a Clinic Near You
Who Is Running the Clinical Trial?
Zimmer Biomet
Lead Sponsor
Dr. Nitin Goyal
Zimmer Biomet
Chief Medical Officer since 2021
MD from Harvard Medical School
Ivan Tornos
Zimmer Biomet
Chief Executive Officer since 2023
MBA from the University of Miami School of Business, BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business